Work

Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.4074

Authors: Jean-Charles Soria, John H. Strickler, Ramaswamy Govindan, Seungjean Chai, Nancy Chan, Vanesa Quiroga-Garcia, Rastislav Bahleda, Cinta Hierro, Bob Zhong, Martha Gonzalez, Ademi E. Santiago-Walker, Trilok V. Parekh, Feng Roger Luo, Loretta Sullivan-Chang, Hong Xie, Josep Tabernero

Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, Duke Medical Center, Duke Cancer Institute, Washington University in St. Louis, Levine Cancer Institute, Rutgers Cancer Institute, Institut Català d'Oncologia, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Janssen Research & Development (United States)

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2767436767

Cites:

Cited by: 24

Related to: 10